A Single-Center, Randomized, Double Masked, Placebo Controlled Clinical Study to Assess the Safety and Efficacy of TOP1630 Ophthalmic Solution Compared to Placebo in Subjects With Dry Eye Syndrome
Phase of Trial: Phase I/II
Latest Information Update: 10 Jul 2017
At a glance
- Drugs TOP 1630 (Primary)
- Indications Dry eyes
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- Sponsors TopiVert
- 05 Jul 2017 Status changed from recruiting to completed.
- 16 Mar 2017 Status changed to recruiting.
- 28 Nov 2016 According to a TopiVert media release, an Investigational New Drug (IND) application for the evaluation of TOP1630 ophthalmic solution as a treatment of patients with dry eye syndrome (DES) has been approved by the US Food and Drug Administration (FDA).